How can REXULTI® help your patients with schizophrenia?

In this short video, Professor Gregory Mattingly summarises how REXULTI® can help improve functional outcomes for patients with schizophrenia.1* He also discusses how he utilises REXULTI® in practice and the benefits he sees in prescribing it for his patients.

*REXULTI® led to a statistically significant improvement in the Personal and Social Performance (PSP) total score compared to placebo after 24 weeks (LOCF, p<0.05) of treatment, an outcome that was sustained through to 52 weeks (LOCF, p<0.01). The PSP score is comprised of four domains: personal and social relationships, disturbing and aggressive behaviours, self-care, and socially useful activities.1,2

References

1. Fleischhacker WW et al. Int J Neuropsychopharmacol 2017; 20: 11–21 (including supplementary material).

The views and opinions expressed in this video do not necessarily reflect those of Lundbeck and Otsuka.

LOCF, last observation carried forward; PSP, Personal and Social Performance scale.

Page: AU-ABIM-0583. September 2024. Video: AU-REXU-0387. November 2023.

  • Box
    Body

    REXULTI PBS Information: Authority required (STREAMLINED). Code: 4246 for schizophrenia

  • text
    Body

    Please review Approved Product Information before prescribing.
    Product Information is available by calling Lundbeck on 1300 721 277 or by clicking:

    REXULTI PI

    REXULTI® is a registered trademark of H. Lundbeck A/S. REXULTI® is co-commercialised by Lundbeck Australia and Otsuka Australia Pharmaceutical Pty Limited.

Related

Related